Bipolar disorder, in full remission, most recent episode depressed
Methodology & AI Transparency ⓘ
Bipolar disorder, in full remission, most recent episode depressed Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as F31.76, Bipolar disorder, in full remission, most recent episode depressed falls under Depression & Mood management, where validated longitudinal mood in Bipolar disorder, in full remission, most recent episode depressed (F31.76: rating scales (PHQ-9) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Bipolar disorder, in full remission, most recent episode depressed uses ICD-10 F31.76 across Depression & Mood specialty care.
- 3 Typical cash cost range: Clinicians assessing Bipolar disorder, in full remission, most recent episode depressed focus on circadian phase instability [Bipolar disorder, in full remission, most recent episode depressed F31.76] and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Bipolar disorder, in full remission, most recent episode depressed: maintaining PHQ-9 Symptom Severity in Bipolar disorder, in full remission, most recent episode depressed (F31.76: Score) within < 4 (clinical remission) (F31.76).
Ask our AI Specialists anything about Bipolar disorder, in full remission, most recent episode depressed
What Is Bipolar disorder, in full remission, most recent episode depressed?
Designated in federal medical registries as F31.76, Bipolar disorder, in full remission, most recent episode depressed falls under Depression & Mood management, where validated longitudinal mood in Bipolar disorder, in full remission, most recent episode depressed (F31.76: rating scales (PHQ-9) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Bipolar disorder, in full remission, most recent episode depressed (F31.76) features circadian phase instability [Bipolar disorder, in full remission, most recent episode depressed F31.76]. therapeutic stabilization in depression & mood is verified against TSH & Free in Bipolar disorder, in full remission, most recent episode depressed (F31.76: T4 Rule-Out).
Common Symptoms & Clinical Signs
- • Presentation of Bipolar disorder, in full remission, most recent episode depressed (F31.76): slowed concentration, indecisiveness, in Bipolar disorder, in full remission, most recent episode depressed (F31.76: and physical heaviness)
- • Secondary Bipolar disorder, in full remission, most recent episode depressed clinical sign: loss of interest in Bipolar disorder, in full remission, most recent episode depressed (F31.76: or pleasure in)
- • Symptom flares in Bipolar disorder, in full remission, most recent episode depressed correlating with PHQ-9 Symptom Severity in Bipolar disorder, in full remission, most recent episode depressed (F31.76: Score) deviation outside < 4 (clinical remission) (F31.76)
- • Functional depression & mood impact requiring validated longitudinal mood in Bipolar disorder, in full remission, most recent episode depressed (F31.76: rating scales (PHQ-9) evaluation (F31.76)
Bipolar disorder, in full remission, most recent episode depressed Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F31.76 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Bipolar disorder, in full remission, most recent episode depressed (F31.76: Score) | < 4 (clinical remission) (F31.76) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Bipolar disorder, in full remission, most recent episode depressed (F31.76: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F31.76) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Bipolar disorder, in full remission, most recent episode depressed (F31.76: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F31.76) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bipolar disorder, in full remission, most recent episode depressed
Treatment selection for Bipolar disorder, in full remission, most recent episode depressed depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bipolar disorder, in full remission, most recent episode depressed)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Concise Health Risk Tracking-Self Report: Psychometrics within a compared against: What a 278-Participant Study Found Change in clinician-rated suicidal thoughts was reflected. Journal of psychopharmacology (Oxford, England) • 2019-02-15 • Randomized Controlled Trial | N = 278 | 93/100 | PMID 30652941 ↗ |
| New Insights on Improvements in irritability with sertraline versus placebo: Findings from the: What a 292-Participant Study Found There was a significant treatment arm-by-time interaction (F = 6.96, df = 6, 1418, p <0.0001) suggesting that changes in irritability with sertraline differed from placebo. Journal of affective disorders • 2020-10-01 • Randomized Controlled Trial | N = 292 | 93/100 | PMID 32658822 ↗ |
| New Insights on Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed: What a 376-Participant Study Found Conclusions: Lumateperone 42 mg significantly improved symptoms of depression and disease severity in patients with an MDE associated with bipolar I or bipolar II disorder, with or without mixed features. The Journal of clinical psychiatry • 2023-04-24 • Phase III Randomized Trial | N = 376 | 93/100 | PMID 37103915 ↗ |
| New Insights on Can personalized treatment prediction improve the outcomes, compared with the: What a 1,544-Participant Study Found The multivariable prediction models led to improved recommendations for a minority of participants than the group average approach in a megatrial. Journal of affective disorders • 2020-09-01 • Randomized Controlled Trial | N = 1,544 | 90/100 | PMID 32664003 ↗ |
| Can This Approach Help? Inside the Latest Research on Duration of Adjunctive Antidepressant Maintenance in Bipolar I In a trial involving patients with bipolar I disorder and a recently remitted depressive episode, adjunctive treatment with escitalopram or bupropion XL that continued for 52 weeks did not show a significant benefit as... The New England journal of medicine • 2023-08-03 • Randomized Controlled Trial | N = 90 | 88/100 | PMID 37530824 ↗ |
Bipolar disorder, in full remission, most recent episode depressed Patient Community & “People Like Me” Threads
Filter Bipolar disorder, in full remission, most recent episode depressed community threads and patient logs by age, biological sex, dosage, and treatment duration.